Zofenopril
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Zofenopril is an ACE inhibitor indicated in the treatment of hypertension.
- Generic Name
- Zofenopril
- DrugBank Accession Number
- DB13166
- Background
Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Zofenopril (DB13166)
- Weight
- Average: 429.55
Monoisotopic: 429.106850573 - Chemical Formula
- C22H23NO4S2
- Synonyms
- Zofenil
- Zofénopril
- Zofenopril
- Zofenoprilum
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AAngiotensin-converting enzyme inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Zofenopril. Aceclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Zofenopril. Acemetacin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Zofenopril. Acetylsalicylic acid The therapeutic efficacy of Zofenopril can be decreased when used in combination with Acetylsalicylic acid. Agrostis gigantea pollen The risk or severity of adverse effects can be increased when Zofenopril is combined with Agrostis gigantea pollen. Agrostis stolonifera pollen The risk or severity of adverse effects can be increased when Zofenopril is combined with Agrostis stolonifera pollen. Alclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alclofenac is combined with Zofenopril. Aldesleukin Aldesleukin may increase the hypotensive activities of Zofenopril. Alfentanil Alfentanil may decrease the antihypertensive activities of Zofenopril. Alfuzosin Alfuzosin may increase the hypotensive activities of Zofenopril. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Zofenopril calcium 88ZQ329PU2 81938-43-4 NSYUKKYYVFVMST-LETVYOFWSA-L - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BIFRIL PLUS Zofenopril (30 MG) + Hydrochlorothiazide (12.5 MG) Tablet, film coated Oral บริษัท เอ. เมนารินี (ประเทศไทย) จำกัด 2017-05-09 Not applicable Thailand 
BIFRIL PLUS 30/12.5 MG FILM TABLET, 28 ADET Zofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg) Tablet, film coated Oral ULAGAYLAR İLAÇ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
BIFRIL PLUS 30/12.5 MG FILM TABLET, 84 ADET Zofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg) Tablet, film coated Oral ULAGAYLAR İLAÇ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ZOPROTEC PLUS 30/12.5 MG FILM TABLET, 28 ADET Zofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg) Tablet, film coated Oral MENARİNİ İLAÇ SANAYİ VE TİCARET A.Ş. 2020-08-14 Not applicable Turkey ZOPROTEC PLUS 30/12.5 MG FILM TABLET, 84 ADET Zofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg) Tablet, film coated Oral MENARİNİ İLAÇ SANAYİ VE TİCARET A.Ş. 2020-08-14 Not applicable Turkey
Categories
- ATC Codes
- C09BA15 — Zofenopril and diuretics
- C09BA — ACE inhibitors and diuretics
- C09B — ACE INHIBITORS, COMBINATIONS
- C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C — CARDIOVASCULAR SYSTEM
- Drug Categories
- ACE Inhibitors and Diuretics
- Acids, Acyclic
- Agents Acting on the Renin-Angiotensin System
- Agents causing angioedema
- Agents causing hyperkalemia
- Amino Acids
- Amino Acids, Cyclic
- Amino Acids, Peptides, and Proteins
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Cardiovascular Agents
- Enzyme Inhibitors
- Imines
- Imino Acids
- Protease Inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Proline and derivatives
- Alternative Parents
- N-acyl-L-alpha-amino acids / Thiobenzoic acids and derivatives / Benzoic acids and derivatives / Thiophenol ethers / Pyrrolidine carboxylic acids / Benzoyl derivatives / N-acylpyrrolidines / Alkylarylthioethers / Tertiary carboxylic acid amides / Thioesters show 10 more
- Substituents
- Alkylarylthioether / Aromatic heteromonocyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzoic acid or derivatives / Benzoyl / Carbonyl group / Carbothioic s-ester / Carboxamide group show 27 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- thioester, aryl sulfide, N-acyl-L-amino acid, L-proline derivative (CHEBI:78539)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 290ZY759PI
- CAS number
- 81872-10-8
- InChI Key
- IAIDUHCBNLFXEF-MNEFBYGVSA-N
- InChI
- InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1
- IUPAC Name
- (2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylic acid
- SMILES
- C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1
References
- General References
- Nilsson P: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:25-30. [Article]
- Mallion JM: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:13-8. [Article]
- AIFA Product Information: Bifril (zofenopril calcium) film-coated tablets [Link]
- External Links
- KEGG Drug
- D08688
- PubChem Compound
- 92400
- PubChem Substance
- 347829273
- ChemSpider
- 83422
- BindingDB
- 50084629
- 39990
- ChEBI
- 78539
- ChEMBL
- CHEMBL331378
- ZINC
- ZINC000003775162
- Wikipedia
- Zofenopril
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment High Blood Pressure (Hypertension) 1 4 Recruiting Treatment Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 15 mg Tablet Oral Tablet, coated Oral 30 mg Tablet, film coated Oral 7.5 mg Tablet, coated Oral Tablet, film coated Oral Tablet, film coated Oral 15 MG Tablet, film coated Oral 30 MG Tablet, film coated Oral 60 MG Tablet, film coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00311 mg/mL ALOGPS logP 3.64 ALOGPS logP 4.31 ChemAxon logS -5.1 ALOGPS pKa (Strongest Acidic) 3.5 ChemAxon pKa (Strongest Basic) -1.3 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 74.68 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 116.82 m3·mol-1 ChemAxon Polarizability 46.1 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
- Gene Name
- ACE
- Uniprot ID
- P12821
- Uniprot Name
- Angiotensin-converting enzyme
- Molecular Weight
- 149713.675 Da
References
- Ambrosioni E: Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7(1):17-24. [Article]
Drug created on February 11, 2017 15:59 / Updated on June 05, 2021 09:12